<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934020</url>
  </required_header>
  <id_info>
    <org_study_id>NHSR-1</org_study_id>
    <nct_id>NCT04934020</nct_id>
  </id_info>
  <brief_title>Global Impact of the COVID 19 Pandemic on Stroke Care, Cerebral Venous Thrombosis, and Subarachnoid Hemorrhage</brief_title>
  <official_title>Global Impact of the COVID 19 Pandemic on Stroke Care: 1-year Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 1-year analysis of global selected stroke metric data will be conducted comparing the&#xD;
      results during the Covid-19 pandemic to the pre-pandemic period. In most countries, this will&#xD;
      correspond to March 1, 2020 to February 28, 2021. In some countries, the pandemic period&#xD;
      would be adjusted for onset of case surge (i.e. China pandemic start date would begin&#xD;
      earlier, i.e. January 2020). The specific metrics that will be analyzed include:&#xD;
&#xD;
        1. ischemic stroke or transient ischemic attacks (TIA) hospitalizations&#xD;
&#xD;
        2. intracranial hemorrhage hospitalizations&#xD;
&#xD;
        3. cerebral venous thrombosis (CVT) hospitalizations (with or without thrombocytopenia)&#xD;
&#xD;
        4. CVT in-hospital mortality&#xD;
&#xD;
      4) aneurysmal subarachnoid hemorrhage hospitalizations 5) mechanical thrombectomy 6)&#xD;
      intravenous thrombolysis 7) ruptured aneurysm endovascular coiling 8) ruptured aneurysm&#xD;
      clipping. 9) aneurysmal subarachnoid hemorrhage admissions 10) SAH in-hospital mortality 11)&#xD;
      SAH presentation by Hunt Hess Grade&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective, observational, cross-sectional, international study, across 6&#xD;
      continents, and estimated 100 stroke centers. The stroke metric diagnoses will be identified&#xD;
      by their International Classification of Diseases version 10 (ICD-10) codes and/or&#xD;
      classifications in stroke databases at participating centers. Aggregate monthly volume will&#xD;
      be obtained from January 1, 2019 to May 31, 2021. For CVT related to COVID vaccine events,&#xD;
      the study period extends until July 30, 2021&#xD;
&#xD;
      The primary hypotheses to be tested are:&#xD;
&#xD;
        -  The overall 1-year volumes of the stroke metrics will be decreased compared to the prior&#xD;
           year.&#xD;
&#xD;
        -  With each subsequent COVID wave, there will be a decline in relation to the prior year&#xD;
           volumes, as was seen with the first COVID-19 wave of the pandemic.&#xD;
&#xD;
        -  A recovery or increase in stroke volume will occur during the vaccine roll-out phase on&#xD;
           same metrics, compared to the immediately preceding period and/or compared to the same&#xD;
           period one year prior.&#xD;
&#xD;
        -  There will be a decline in mild clinical severity in the presentation of patients with&#xD;
           subarachnoid hemorrhage as measured by the Hunt Hess Grade scale, parallel to the&#xD;
           decline in mild severity of stroke admissions seen with the first wave of the pandemic.&#xD;
           [Mild severity of presentation is defined as Hunt Hess Grade 0-2, moderate to severe is&#xD;
           defined as Hunt Hess Grade 3-5.]&#xD;
&#xD;
        -  There will be an increase of CVT diagnosis during the COVID-19 pandemic year, related&#xD;
           either to heightened awareness of COVID-19 and thrombotic events, or related to reported&#xD;
           associations of CVT and COVID-19.&#xD;
&#xD;
      The ICD codes utilized for the diagnosis are as follows:&#xD;
&#xD;
      Ischemic Stroke, ICD-10 Codes&#xD;
&#xD;
      I63.0 Cerebral Infarction&#xD;
&#xD;
      I63.1 Cerebral infarction due to embolism of precerebral arteries&#xD;
&#xD;
      I63.2 Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries&#xD;
&#xD;
      I63.3 Cerebral infarction due to thrombosis of cerebral arteries&#xD;
&#xD;
      I63.4 Cerebral infarction due to embolism of cerebral arteries&#xD;
&#xD;
      I63.5 Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries&#xD;
&#xD;
      I63.8 Other cerebral infarction&#xD;
&#xD;
      I63.9 Cerebral infarction, unspecified&#xD;
&#xD;
      Intracranial Hemorrhage, ICD-10 Codes&#xD;
&#xD;
      I61 Nontraumatic intracerebral hemorrhage&#xD;
&#xD;
      I61.0 Nontraumatic intracerebral hemorrhage in hemisphere, subcortical&#xD;
&#xD;
      I61.1 Nontraumatic intracerebral hemorrhage in hemisphere, cortical&#xD;
&#xD;
      I61.2 Nontraumatic intracerebral hemorrhage in hemisphere, unspecified&#xD;
&#xD;
      I61.3 Nontraumatic intracerebral hemorrhage in brain stem&#xD;
&#xD;
      I61.4 Nontraumatic intracerebral hemorrhage in cerebellum&#xD;
&#xD;
      I61.5 Nontraumatic intracerebral hemorrhage, intraventricular&#xD;
&#xD;
      I61.6 Nontraumatic intracerebral hemorrhage, multiple localized&#xD;
&#xD;
      I61.8 Other nontraumatic intracerebral hemorrhage&#xD;
&#xD;
      I61.9 Nontraumatic intracerebral hemorrhage, unspecified&#xD;
&#xD;
      Cerebral Venous thrombosis, Codes&#xD;
&#xD;
      G08 Intracranial Phlebitis and Thromboplhlebitis I63.6 Cerebral infarction due to cerebral&#xD;
      venous thrombosis, nonpyogenic I67.6 Nonpyogenic Thrombosis of Intracranial Venous System&#xD;
      O22.5 Cerebral venous thrombosis in pregnancy&#xD;
&#xD;
      Subarachnoid Hemorrhage, Codes&#xD;
&#xD;
      I60.0 Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation&#xD;
&#xD;
      I60.1 Nontraumatic subarachnoid hemorrhage from middle cerebral artery&#xD;
&#xD;
      I60.2 Nontraumatic subarachnoid hemorrhage from anterior communicating artery&#xD;
&#xD;
      I60.3 Nontraumatic subarachnoid hemorrhage from posterior communicating artery&#xD;
&#xD;
      I60.4 Nontraumatic subarachnoid hemorrhage from basilar artery&#xD;
&#xD;
      I60.5 Nontraumatic subarachnoid hemorrhage from vertebral artery&#xD;
&#xD;
      I60.6 Nontraumatic subarachnoid hemorrhage from other intracranial arteries&#xD;
&#xD;
      I60.7 Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery&#xD;
&#xD;
      I60.8 Other nontraumatic subarachnoid hemorrhage&#xD;
&#xD;
      I60.9 Nontraumatic subarachnoid hemorrhage, unspecified&#xD;
&#xD;
      COVID19&#xD;
&#xD;
      UO7.1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 25, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Trends in stroke metrics before and during the covid pandemic</measure>
    <time_frame>12 months</time_frame>
    <description>2- to 3-month trends in stroke metrics with COVID 2nd or 3rd waves in each country, using the Hopkins website to define waves of either the state or country with which the center is located https://coronavirus.jhu.edu/data/new-cases and compare to same period prior year A wave or phase is defined as a rising number of COVID-19 cases with a defined peak, followed by a decline in cases or trough period, in which transmission had decreased.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccination impact on stroke metrics</measure>
    <time_frame>12 months</time_frame>
    <description>The interaction between the vaccine roll-out phase on stroke metrics will be assessed, adjusted by country month in which 10% of population has been vaccinated with at least 1 dose using vaccine tracker data from https://ourworldindata.org/covid-vaccinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of subarachnoid hemorrhage presentation</measure>
    <time_frame>12 months</time_frame>
    <description>The severity of presentation of patients with subarachnoid hemorrhage will be assessed using the Hunt Hess Grade which is a graded scale used to predict the rate of mortality based solely on the clinical features seen in a patient presenting with an aneurysmal subarachnoid hemorrhage. There are grades 0 to 6: 0=Unruptured aneurysm without symptoms; 1=Asymptomatic or minimal headache with slight nuchal rigidity; 1a=No acute meningeal or brain reaction but with fixed neurological deficit; 2=Moderate to severe headache, nuchal rigidity, no neurological deficits other than cranial nerve palsy; 3=Drowsy, confused, or mild focal deficit; 4=stupor, moderate to severe hemiparesis, possible early decerebrate rigidity, and vegetative disturbances; 5=Deep coma, decerebrate rigidity, moribund. Higher grades are correlated with greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subarachnoid hemorrhage clinical outcome</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical outcome will be assessed by rates of in-hospital mortality and discharge to hospice abstracted from medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral venous thrombosis (CVT)</measure>
    <time_frame>March 2019 to February 2020, March 2020 to December 2020, January 2021 to May 31, 2021</time_frame>
    <description>Morality, thrombocytopenia (&lt;150K) related to CVT will be assessed prior to, and during the COVID-19 pandemic, and during the vaccine roll-out phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CVT related thrombocytopenia</measure>
    <time_frame>March 2019 to February 2020, March 2020 to December 2020, January 2021 to May 31, 2021</time_frame>
    <description>Thrombocytopenia related to CVT will be assessed pre-COVID, during COVID, and post vaccine roll-out phases</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Stroke</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pre-pandemic stroke related metrics</intervention_name>
    <description>De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stroke related metrics during the pandemic</intervention_name>
    <description>De-identified data from selected stroke metrics identified by ICD-10 codes will be abstracted from medical records of stroke patients in about 200 stroke centers in 6 continents.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        De-identified data from selected stroke metrics identified by ICD-10 codes from medical&#xD;
        records of stroke patients in about 100 to 300 stroke centers in 6 continents will be&#xD;
        analyzed.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Received stroke related care during the study period in one of the stroke centers&#xD;
             across 6 continents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thanh N Nguyen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul G Nogueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grady Memorial Hospital, Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Memorial Hospital, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nogueira RG, Abdalkader M, Qureshi MM, Frankel MR, Mansour OY, Yamagami H, Qiu Z, Farhoudi M, Siegler JE, Yaghi S, Raz E, Sakai N, Ohara N, Piotin M, Mechtouff L, Eker O, Chalumeau V, Kleinig TJ, Pop R, Liu J, Winters HS, Shang X, Vasquez AR, Blasco J, Arenillas JF, Martinez-Galdamez M, Brehm A, Psychogios MN, Lylyk P, Haussen DC, Al-Bayati AR, Mohammaden MH, Fonseca L, Luís Silva M, Montalverne F, Renieri L, Mangiafico S, Fischer U, Gralla J, Frei D, Chugh C, Mehta BP, Nagel S, Mohlenbruch M, Ortega-Gutierrez S, Farooqui M, Hassan AE, Taylor A, Lapergue B, Consoli A, Campbell BC, Sharma M, Walker M, Van Horn N, Fiehler J, Nguyen HT, Nguyen QT, Watanabe D, Zhang H, Le HV, Nguyen VQ, Shah R, Devlin T, Khandelwal P, Linfante I, Izzath W, Lavados PM, Olavarría VV, Sampaio Silva G, de Carvalho Sousa AV, Kirmani J, Bendszus M, Amano T, Yamamoto R, Doijiri R, Tokuda N, Yamada T, Terasaki T, Yazawa Y, Morris JG, Griffin E, Thornton J, Lavoie P, Matouk C, Hill MD, Demchuk AM, Killer-Oberpfalzer M, Nahab F, Altschul D, Ramos-Pachón A, Pérez de la Ossa N, Kikano R, Boisseau W, Walker G, Cordina SM, Puri A, Luisa Kuhn A, Gandhi D, Ramakrishnan P, Novakovic-White R, Chebl A, Kargiotis O, Czap A, Zha A, Masoud HE, Lopez C, Ozretic D, Al-Mufti F, Zie W, Duan Z, Yuan Z, Huang W, Hao Y, Luo J, Kalousek V, Bourcier R, Guile R, Hetts S, Al-Jehani HM, AlHazzani A, Sadeghi-Hokmabadi E, Teleb M, Payne J, Lee JS, Hong JM, Sohn SI, Hwang YH, Shin DH, Roh HG, Edgell R, Khatri R, Smith A, Malik A, Liebeskind D, Herial N, Jabbour P, Magalhaes P, Ozdemir AO, Aykac O, Uwatoko T, Dembo T, Shimizu H, Sugiura Y, Miyashita F, Fukuda H, Miyake K, Shimbo J, Sugimura Y, Beer-Furlan A, Joshi K, Catanese L, Abud DG, Neto OG, Mehrpour M, Al Hashmi A, Saqqur M, Mostafa A, Fifi JT, Hussain S, John S, Gupta R, Sivan-Hoffmann R, Reznik A, Sani AF, Geyik S, Akıl E, Churojana A, Ghoreishi A, Saadatnia M, Sharifipour E, Ma A, Faulder K, Wu T, Leung L, Malek A, Voetsch B, Wakhloo A, Rivera R, Barrientos Iman DM, Pikula A, Lioutas VA, Thomalla G, Birnbaum L, Machi P, Bernava G, McDermott M, Kleindorfer D, Wong K, Patterson MS, Fiorot JA Jr, Huded V, Mack W, Tenser M, Eskey C, Multani S, Kelly M, Janardhan V, Cornett O, Singh V, Murayama Y, Mokin M, Yang P, Zhang X, Yin C, Han H, Peng Y, Chen W, Crosa R, Frudit ME, Pandian JD, Kulkarni A, Yagita Y, Takenobu Y, Matsumaru Y, Yamada S, Kono R, Kanamaru T, Yamazaki H, Sakaguchi M, Todo K, Yamamoto N, Sonoda K, Yoshida T, Hashimoto H, Nakahara I, Cora E, Volders D, Ducroux C, Shoamanesh A, Ospel J, Kaliaev A, Ahmed S, Rashid U, Rebello LC, Pereira VM, Fahed R, Chen M, Sheth SA, Palaiodimou L, Tsivgoulis G, Chandra R, Koyfman F, Leung T, Khosravani H, Dharmadhikari S, Frisullo G, Calabresi P, Tsiskaridze A, Lobjanidze N, Grigoryan M, Czlonkowska A, de Sousa DA, Demeestere J, Liang C, Sangha N, Lutsep HL, Ayo-Martín Ó, Cruz-Culebras A, Tran AD, Young CY, Cordonnier C, Caparros F, De Lecinana MA, Fuentes B, Yavagal D, Jovin T, Spelle L, Moret J, Khatri P, Zaidat O, Raymond J, Martins S, Nguyen T. Global impact of COVID-19 on stroke care. Int J Stroke. 2021 Jul;16(5):573-584. doi: 10.1177/1747493021991652. Epub 2021 Mar 29.</citation>
    <PMID>33459583</PMID>
  </reference>
  <reference>
    <citation>Nguyen TN, Haussen DC, Qureshi MM, Yamagami H, Fujinaka T, Mansour OY, Abdalkader M, Frankel M, Qiu Z, Taylor A, Lylyk P, Eker OF, Mechtouff L, Piotin M, Lima FO, Mont'Alverne F, Izzath W, Sakai N, Mohammaden M, Al-Bayati AR, Renieri L, Mangiafico S, Ozretic D, Chalumeau V, Ahmad S, Rashid U, Hussain SI, John S, Griffin E, Thornton J, Fiorot JA, Rivera R, Hammami N, Cervantes-Arslanian AM, Dasenbrock HH, Vu HL, Nguyen VQ, Hetts S, Bourcier R, Guile R, Walker M, Sharma M, Frei D, Jabbour P, Herial N, Al-Mufti F, Ozdemir AO, Aykac O, Gandhi D, Chugh C, Matouk C, Lavoie P, Edgell R, Beer-Furlan A, Chen M, Killer-Oberpfalzer M, Pereira VM, Nicholson P, Huded V, Ohara N, Watanabe D, Shin DH, Magalhaes PS, Kikano R, Ortega-Gutierrez S, Farooqui M, Abou-Hamden A, Amano T, Yamamoto R, Weeks A, Cora EA, Sivan-Hoffmann R, Crosa R, Möhlenbruch M, Nagel S, Al-Jehani H, Sheth SA, Lopez Rivera VS, Siegler JE, Sani AF, Puri AS, Kuhn AL, Bernava G, Machi P, Abud DG, Pontes-Neto OM, Wakhloo AK, Voetsch B, Raz E, Yaghi S, Mehta BP, Kimura N, Murakami M, Lee JS, Hong JM, Fahed R, Walker G, Hagashi E, Cordina SM, Roh HG, Wong K, Arenillas JF, Martinez-Galdamez M, Blasco J, Rodriguez Vasquez A, Fonseca L, Silva ML, Wu TY, John S, Brehm A, Psychogios M, Mack WJ, Tenser M, Todaka T, Fujimura M, Novakovic R, Deguchi J, Sugiura Y, Tokimura H, Khatri R, Kelly M, Peeling L, Murayama Y, Winters HS, Wong J, Teleb M, Payne J, Fukuda H, Miyake K, Shimbo J, Sugimura Y, Uno M, Takenobu Y, Matsumaru Y, Yamada S, Kono R, Kanamaru T, Morimoto M, Iida J, Saini V, Yavagal D, Bushnaq S, Huang W, Linfante I, Kirmani J, Liebeskind DS, Szeder V, Shah R, Devlin TG, Birnbaum L, Luo J, Churojana A, Masoud HE, Lopez CY, Steinfort B, Ma A, Hassan AE, Al Hashmi A, McDermott M, Mokin M, Chebl A, Kargiotis O, Tsivgoulis G, Morris JG, Eskey CJ, Thon J, Rebello L, Altschul D, Cornett O, Singh V, Pandian J, Kulkarni A, Lavados PM, Olavarria VV, Todo K, Yamamoto Y, Silva GS, Geyik S, Johann J, Multani S, Kaliaev A, Sonoda K, Hashimoto H, Alhazzani A, Chung DY, Mayer SA, Fifi JT, Hill MD, Zhang H, Yuan Z, Shang X, Castonguay AC, Gupta R, Jovin TG, Raymond J, Zaidat OO, Nogueira RG; SVIN COVID-19 Registry, the Middle East North Africa Stroke and Interventional Neurotherapies Organization (MENA-SINO); Japanese Society of Vascular and Interventional Neurology Society (JVIN). Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemic. Stroke Vasc Neurol. 2021 Mar 26. pii: svn-2020-000695. doi: 10.1136/svn-2020-000695. [Epub ahead of print]</citation>
    <PMID>33771936</PMID>
  </reference>
  <reference>
    <citation>Nogueira RG, Qureshi MM, Abdalkader M, Martins SO, Yamagami H, Qiu Z, Mansour OY, Sathya A, Czlonkowska A, Tsivgoulis G, Aguiar de Sousa D, Demeestere J, Mikulik R, Vanacker P, Siegler JE, Kõrv J, Biller J, Liang CW, Sangha NS, Zha AM, Czap AL, Holmstedt CA, Turan TN, Ntaios G, Malhotra K, Tayal A, Loochtan A, Ranta A, Mistry EA, Alexandrov AW, Huang DY, Yaghi S, Raz E, Sheth SA, Mohammaden MH, Frankel M, Bila Lamou EG, Aref HM, Elbassiouny A, Hassan F, Menecie T, Mustafa W, Shokri HM, Roushdy T, Sarfo FS, Alabi TO, Arabambi B, Nwazor EO, Sunmonu TA, Wahab K, Yaria J, Mohammed HH, Adebayo PB, Riahi AD, Sassi SB, Gwaunza L, Ngwende GW, Sahakyan D, Rahman A, Ai Z, Bai F, Duan Z, Hao Y, Huang W, Li G, Li W, Liu G, Luo J, Shang X, Sui Y, Tian L, Wen H, Wu B, Yan Y, Yuan Z, Zhang H, Zhang J, Zhao W, Zi W, Leung TW, Chugh C, Huded V, Menon B, Pandian JD, Sylaja PN, Usman FS, Farhoudi M, Hokmabadi ES, Horev A, Reznik A, Sivan Hoffmann R, Ohara N, Sakai N, Watanabe D, Yamamoto R, Doijiri R, Tokuda N, Yamada T, Terasaki T, Yazawa Y, Uwatoko T, Dembo T, Shimizu H, Sugiura Y, Miyashita F, Fukuda H, Miyake K, Shimbo J, Sugimura Y, Yagita Y, Takenobu Y, Matsumaru Y, Yamada S, Kono R, Kanamaru T, Yamazaki H, Sakaguchi M, Todo K, Yamamoto N, Sonoda K, Yoshida T, Hashimoto H, Nakahara I, Kondybayeva A, Faizullina K, Kamenova S, Zhanuzakov M, Baek JH, Hwang Y, Lee JS, Lee SB, Moon J, Park H, Seo JH, Seo KD, Sohn SI, Young CJ, Ahdab R, Wan Zaidi WA, Aziz ZA, Basri HB, Chung LW, Ibrahim AB, Ibrahim KA, Looi I, Tan WY, Yahya NW, Groppa S, Leahu P, Al Hashmi AM, Imam YZ, Akhtar N, Pineda-Franks MC, Co CO, Kandyba D, Alhazzani A, Al-Jehani H, Tham CH, Mamauag MJ, Venketasubramanian N, Chen CH, Tang SC, Churojana A, Akil E, Aykaç Ö, Ozdemir AO, Giray S, Hussain SI, John S, Le Vu H, Tran AD, Nguyen HH, Nhu Pham T, Nguyen TH, Nguyen TQ, Gattringer T, Enzinger C, Killer-Oberpfalzer M, Bellante F, De Blauwe S, Vanhooren G, De Raedt S, Dusart A, Lemmens R, Ligot N, Pierre Rutgers M, Yperzeele L, Alexiev F, Sakelarova T, Bedeković MR, Budincevic H, Cindric I, Hucika Z, Ozretic D, Saric MS, Pfeifer F, Karpowic I, Cernik D, Sramek M, Skoda M, Hlavacova H, Klecka L, Koutny M, Vaclavik D, Skoda O, Fiksa J, Hanelova K, Nevsimalova M, Rezek R, Prochazka P, Krejstova G, Neumann J, Vachova M, Brzezanski H, Hlinovsky D, Tenora D, Jura R, Jurák L, Novak J, Novak A, Topinka Z, Fibrich P, Sobolova H, Volny O, Krarup Christensen H, Drenck N, Klingenberg Iversen H, Simonsen CZ, Truelsen TC, Wienecke T, Vibo R, Gross-Paju K, Toomsoo T, Antsov K, Caparros F, Cordonnier C, Dan M, Faucheux JM, Mechtouff L, Eker O, Lesaine E, Ondze B, Peres R, Pico F, Piotin M, Pop R, Rouanet F, Gubeladze T, Khinikadze M, Lobjanidze N, Tsiskaridze A, Nagel S, Ringleb PA, Rosenkranz M, Schmidt H, Sedghi A, Siepmann T, Szabo K, Thomalla G, Palaiodimou L, Sagris D, Kargiotis O, Klivenyi P, Szapary L, Tarkanyi G, Adami A, Bandini F, Calabresi P, Frisullo G, Renieri L, Sangalli D, Pirson A, Uyttenboogaart M, van den Wijngaard I, Kristoffersen ES, Brola W, Fudala M, Horoch-Lyszczarek E, Karlinski M, Kazmierski R, Kram P, Rogoziewicz M, Kaczorowski R, Luchowski P, Sienkiewicz-Jarosz H, Sobolewski P, Fryze W, Wisniewska A, Wiszniewska M, Ferreira P, Ferreira P, Fonseca L, Marto JP, Pinho E Melo T, Nunes AP, Rodrigues M, Tedim Cruz V, Falup-Pecurariu C, Krastev G, Mako M, de Leciñana MA, Arenillas JF, Ayo-Martin O, Cruz Culebras A, Tejedor ED, Montaner J, Pérez-Sánchez S, Tola Arribas MA, Rodriguez Vasquez A, Mayza M, Bernava G, Brehm A, Machi P, Fischer U, Gralla J, Michel PL, Psychogios MN, Strambo D, Banerjee S, Krishnan K, Kwan J, Butt A, Catanese L, Demchuk AM, Field T, Haynes J, Hill MD, Khosravani H, Mackey A, Pikula A, Saposnik G, Scott CA, Shoamanesh A, Shuaib A, Yip S, Barboza MA, Barrientos JD, Portillo Rivera LI, Gongora-Rivera F, Novarro-Escudero N, Blanco A, Abraham M, Alsbrook D, Altschul D, Alvarado-Ortiz AJ, Bach I, Badruddin A, Barazangi N, Brereton C, Castonguay A, Chaturvedi S, Chaudry SA, Choe H, Choi JH, Dharmadhikari S, Desai K, Devlin TG, Doss VT, Edgell R, Etherton M, Farooqui M, Frei D, Gandhi D, Grigoryan M, Gupta R, Hassan AE, Helenius J, Kaliaev A, Kaushal R, Khandelwal P, Khawaja AM, Khoury NN, Kim BS, Kleindorfer DO, Koyfman F, Lee VH, Leung LY, Linares G, Linfante I, Lutsep HL, Macdougall L, Male S, Malik AM, Masoud H, McDermott M, Mehta BP, Min J, Mittal M, Morris JG, Multani SS, Nahab F, Nalleballe K, Nguyen CB, Novakovic-White R, Ortega-Gutierrez S, Rahangdale RH, Ramakrishnan P, Romero JR, Rost N, Rothstein A, Ruland S, Shah R, Sharma M, Silver B, Simmons M, Singh A, Starosciak AK, Strasser SL, Szeder V, Teleb M, Tsai JP, Voetsch B, Balaguera O, Pujol Lereis VA, Luraschi A, Almeida MS, Cardoso FB, Conforto A, De Deus Silva L, Varrone Giacomini L, Oliveira Lima F, Longo AL, Magalhães PSC, Martins RT, Mont'alverne F, Mora Cuervo DL, Costa Rebello L, Valler L, Zetola VF, Lavados PM, Navia V, Olavarría VV, Almeida Toro JM, Amaya PFR, Bayona H, Corredor A, Rivera Ordonez CE, Mantilla Barbosa DK, Lara O, Patiño MR, Diaz Escobar LF, Dejesus Melgarejo Fariña DE, Cardozo Villamayor A, Zelaya Zarza AJ, Barrientos Iman DM, Rodriguez Kadota L, Campbell B, Hankey GJ, Hair C, Kleinig T, Ma A, Tomazini Martins R, Sahathevan R, Thijs V, Salazar D, Yuan-Hao Wu T, Haussen DC, Liebeskind D, Yavagal DR, Jovin TG, Zaidat OO, Nguyen TN; SVIN COVID-19 Global Stroke Registry; SVIN COVID-19 Global Stroke Registry. Global Impact of COVID-19 on Stroke Care and IV Thrombolysis. Neurology. 2021 Jun 8;96(23):e2824-e2838. doi: 10.1212/WNL.0000000000011885. Epub 2021 Mar 25.</citation>
    <PMID>33766997</PMID>
  </reference>
  <reference>
    <citation>Abdalkader M, Shaikh SP, Siegler JE, Cervantes-Arslanian AM, Tiu C, Radu RA, Tiu VE, Jillella DV, Mansour OY, Vera V, Chamorro Á, Blasco J, López A, Farooqui M, Thau L, Smith A, Gutierrez SO, Nguyen TN, Jovin TG. Cerebral Venous Sinus Thrombosis in COVID-19 Patients: A Multicenter Study and Review of Literature. J Stroke Cerebrovasc Dis. 2021 Jun;30(6):105733. doi: 10.1016/j.jstrokecerebrovasdis.2021.105733. Epub 2021 Mar 4.</citation>
    <PMID>33743411</PMID>
  </reference>
  <reference>
    <citation>Siegler JE, Cardona P, Arenillas JF, Talavera B, Guillen AN, Chavarría-Miranda A, de Lera M, Khandelwal P, Bach I, Patel P, Singla A, Requena M, Ribo M, Jillella DV, Rangaraju S, Nogueira RG, Haussen DC, Vazquez AR, Urra X, Chamorro Á, Román LS, Thon JM, Then R, Sanborn E, de la Ossa NP, Millàn M, Ruiz IN, Mansour OY, Megahed M, Tiu C, Terecoasa EO, Radu RA, Nguyen TN, Curiale G, Kaliaev A, Czap AL, Sebaugh J, Zha AM, Liebeskind DS, Ortega-Gutierrez S, Farooqui M, Hassan AE, Preston L, Patterson MS, Bushnaq S, Zaidat O, Jovin TG. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry. Int J Stroke. 2021 Jun;16(4):437-447. doi: 10.1177/1747493020959216. Epub 2020 Sep 30.</citation>
    <PMID>32852257</PMID>
  </reference>
  <reference>
    <citation>Ortega-Gutierrez S, Farooqui M, Zha A, Czap A, Sebaugh J, Desai S, Jadhav A, Vora N, Rai V, Jovin TG, Thon JM, Heslin M, Thau L, Zevallos C, Quispe-Orozco D, Jillella DV, Nahab F, Mohammaden MH, Nogueira RG, Haussen DC, Nguyen TN, Romero JR, Aparicio HJ, Osman M, Haq IU, Liebeskind D, Hassan AE, Zaidat O, Siegler JE; SVIN COVID-19 Multinational Registry and Task Force. Decline in mild stroke presentations and intravenous thrombolysis during the COVID-19 pandemic: The Society of Vascular and Interventional Neurology Multicenter Collaboration. Clin Neurol Neurosurg. 2021 Feb;201:106436. doi: 10.1016/j.clineuro.2020.106436. Epub 2020 Dec 15.</citation>
    <PMID>33383463</PMID>
  </reference>
  <reference>
    <citation>Ramos-Araque ME, Siegler JE, Ribo M, Requena M, López C, de Lera M, Arenillas JF, Pérez IH, Gómez-Vicente B, Talavera B, Portela PC, Guillen AN, Urra X, Llull L, Renú A, Nguyen TN, Jillella D, Nahab F, Nogueira R, Haussen D, Then R, Thon JM, Esparragoza LR, Hernández-Pérez M, Bustamante A, Mansour OY, Megahed M, Hassan T, Liebeskind DS, Hassan A, Bushnaq S, Osman M, Vazquez AR; SVIN Multinational Registry and Task Force. Stroke etiologies in patients with COVID-19: the SVIN COVID-19 multinational registry. BMC Neurol. 2021 Jan 30;21(1):43. doi: 10.1186/s12883-021-02075-1.</citation>
    <PMID>33514335</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic stroke hospitalizations</keyword>
  <keyword>TIA hospitalizations</keyword>
  <keyword>Intracranial hemorrhage hospitalizations</keyword>
  <keyword>Cerebral venous thrombosis hospitalizations</keyword>
  <keyword>Aneurysmal subarachnoid hemorrhage hospitalizations</keyword>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Intravenous thrombolysis</keyword>
  <keyword>Ruptured aneurysm endovascular coiling</keyword>
  <keyword>Ruptured aneurysm clipping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

